Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Optibrium logo — elegant software that guides successful drug discovery

Optibrium

elegant software that guides successful drug discovery

Founded 2009 United Kingdom Cambridge, United Kingdom 46 employees Private Equity Total: $1.00M

General Information

Company Name Optibrium
Founded Year 2009
Location United Kingdom Cambridge, United Kingdom
Employees 46
Funding Stage Private Equity
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Tiered Pricing, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Optibrium. To contact Optibrium, visit optibrium.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Sep 16, 2026

Optibrium is participating in EuroQSAR, where they will be at booth #9 and Bailey Montefiore will present a poster.

Get alerts when Optibrium shows new signals

About Optibrium

Optibrium, founded in 2009 and headquartered in Cambridge, UK, offers software solutions that enhance the efficiency and productivity of small molecule drug discovery. With its flagship product, StarDrop™, Optibrium provides an integrated software suite delivering predictive modeling and decision-making capabilities. The company's latest innovation, Augmented Chemistry™, leverages artificial intelligence to advance the drug discovery process by learning from existing data.

Optibrium collaborates with a diverse range of partners, including pharmaceutical, agrochemical, and academic institutions worldwide, underscoring its strong industry presence. The company attracted Private Equity Round investment from Kester Capital on June 21, 2022, demonstrating investor confidence in its innovative solutions. Positioned at the intersection of AI and biosciences, Optibrium's continuous focus on research and development is poised to drive significant advancements in drug discovery.

Taxonomy: drug discovery software, small molecule design, optimisation, StarDrop, predictive modelling, Augmented Chemistry, computational chemistry, medicinal chemistry, cheminformatics, de novo design, 3D drug design, metabolism prediction, generative chemistry

Services & Products

AI-guided drug discovery
Real-time collaboration for molecular design
3D ligand-based and structure-based design
Metabolism insights for DMPK scientists
Chemical discovery pipeline optimization

Target Customers

Pharmaceutical companies Biotechnology firms Medicinal chemists DMPK scientists R&D teams in chemical and drug discovery

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 1
Kester Capital
Kester Capital
21 Jun 2022
Private Equity Round Undisclosed 1
Kester Capital
Kester Capital
08 Feb 2021
Grant £1.00M 1
Innovate UK
Innovate UK
19 Sep 2018

Optibrium Alternatives & Competitors

View All Alternatives
Optibrium vs
Oxford Drug Design
Oxford Drug Design United Kingdom

A drug-discovery company focused on oncology, with a unique and powerful combination of expertise th...

12 employees
Biotechnology, Pharmaceutical
Optibrium vs
Anagenex
Anagenex United States

Evolving new small molecule medicines by combining ultra high throughput biochemistry and machine le...

Series A
5 employees
Optibrium vs
Raven biosciences
Raven biosciences Denmark

Custom AI systems for pharma and life-sciences

Seed
8 employees
AI, Biotechnology
View all alternatives

FAQ About Optibrium

elegant software that guides successful drug discovery
Optibrium was founded in 2009.
Optibrium is headquartered in Cambridge, United Kingdom.
Optibrium has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Tiered Pricing and Licensing.
Optibrium has approximately 46 employees.
Optibrium has completed 3 funding rounds, raising a total of $1.00M. The latest funding stage is Private Equity.
Optibrium offers: AI-guided drug discovery, Real-time collaboration for molecular design, 3D ligand-based and structure-based design, Metabolism insights for DMPK scientists, Chemical discovery pipeline optimization.
Top alternatives and competitors to Optibrium include Oxford Drug Design, Anagenex, Raven biosciences, Nimbus Therapeutics, Deargen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Optibrium and Oxford Drug Design are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Optibrium, https://bouncewatch.com/company/optibrium, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes